Navigation Links
Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
Date:11/4/2008

ing statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
2. Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
3. Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
4. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
5. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
7. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
8. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
9. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
10. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
11. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... North Shore Towers, a luxury co-op community based ... one of the nation’s leading combined heating and power (CHP) ... 43-year-old CHP system. The original CHP system had been maintained ... the life of the plant, GI Energy was contracted to ... recovery equipment, while maintaining continuous operation of the entire complex. ...
(Date:7/31/2014)... -- Research and Markets has announced the ... report to their offering. ... the genetic material or genomes of an organism. It ... discovery and development of diagnostic and therapeutic solutions for ... is supported by three major product segments: Instruments, Consumables, ...
(Date:7/31/2014)... July 31, 2014 Senomyx , ... company using proprietary taste science technologies to discover, ... food, beverage, and ingredient supply industries, today reported ... Company ended the second quarter with $33.6 million ... "During the past quarter Senomyx achieved another ...
(Date:7/31/2014)... SHENZHEN, China , July 31, 2014 ... an Irys™System by BGI , the ... enable comprehensive exploration of human structural variation (SV) and ... interest, including those where no reference exists. In addition, ... methods for multiplexing on the Irys System, enabling significantly ...
Breaking Biology Technology:North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4
... 2011 Sigma Life Science, the innovative biological ...  SIAL), and King,s College London, today announced an ... for the identification and validation of microRNA (miRNA) ... detailed information, visit www.wherebiobegins.com/targetid . ...
... Reportlinker.com announces that a new market research report is available ... http://www.reportlinker.com/p0489604/Genetics-Reports-Bundle.html Report Description ... TriMark Publications reports at a15% discount off the individual reports being ... DNA Sequencing and PCR Markets. - Gene Expression ...
... Highlights First Quarter 2011: First ... to Alexandria Real Estate Equities, Inc.,s Common Stockholders of $1.15, ... Up 6% Compared to First Quarter 2010 FFO Per Share ... (Diluted) Attributable to Alexandria Real Estate Equities, Inc.,s Common Stockholders ...
Cached Biology Technology:Sigma® Life Science and King's College London Co-Developing miRNA Target Identification Technology 2Sigma® Life Science and King's College London Co-Developing miRNA Target Identification Technology 3Sigma® Life Science and King's College London Co-Developing miRNA Target Identification Technology 4Reportlinker Adds Genetics Reports Bundle 2Reportlinker Adds Genetics Reports Bundle 3Reportlinker Adds Genetics Reports Bundle 4Reportlinker Adds Genetics Reports Bundle 5Reportlinker Adds Genetics Reports Bundle 6Reportlinker Adds Genetics Reports Bundle 7Reportlinker Adds Genetics Reports Bundle 8Reportlinker Adds Genetics Reports Bundle 9Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 2Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 3Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 4Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 5Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 6Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 7Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 8Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 9Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 10Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 11Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 12Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 13Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 14Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 15Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 16
(Date:8/1/2014)... the UC Davis Center for Neuroscience and Department ... and Engineering Faculty Fellowship from the U.S. Department ... support new work on learning and memory in ... The new project aims to connect neural oscillations, ... the cortex and hippocampus, brain regions that are ...
(Date:8/1/2014)... marine mammals have officially named a species new ... sahulensis , according to the Wildlife Conservation Society ... the newly named species is the culmination of ... historical records, physical descriptions, and genetic data of ... from the coast of West Africa to the ...
(Date:8/1/2014)... in stem cell research will provide enormous opportunities ... stem cells could replicate any other cells in ... disease, repairing damaged spinal cords, treating kidney, liver ... The potential for profit is staggering. Prof. Jinhui ... this field of research still faces myriad biological, ...
Breaking Biology News(10 mins):Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
... (PHILADELPHIA) Scientists at Jefferson Medical College have received ... funded by the National Heart, Lung and Blood Institute ... of platelet gene expression. The study aims to find ... strategies and develop better predictors of cardiovascular disease. ...
... Researchers have tracked a cell-to-cell signaling pathway that designates ... embryonic mice. The scientists succeeded in activating this signal ... inner ear. Patches of sensory structures began growing in ... structures contained tufted cells, called hair cells, which respond ...
... New ground broken by Michigan State University biochemists ... temperatures and could lead to discoveries related to ... "This brings together two classic problems in ... biochemistry and molecular biology. "One is that plants ...
Cached Biology News:Jefferson receives $3 million NIH grant to study molecular and genetic mechanisms in platelets 2Tuning into cell signals that tell where sensory organs will form inside the ear 2Tuning into cell signals that tell where sensory organs will form inside the ear 3Researchers discover novel mechanism protecting plants against freezing 2
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
dithiothreitol, sulfhydryl reducing agent, C4H10O2S2; MW: 154.24, 97% pure (minimum), CAS No: 27565-41-9, store at -20 C ...
... the simple, phenol-free extraction of genomic DNA ... proteinase K digestion.Each kit is designed to ... of up to 25 mg of hard ... and Amplification of Genomic DNA, Nucleon DNA ...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: